BCR and B-cell chronic lymphocytic leukemia: Moreover, we tested responses of these cell lines to the novel targeted B cell receptor (BCR) signaling inhibitors such as ibrutinib and idelalisib, which were initially approved specifically for del(17p)/TP53‐mutated CLL patients.